Open Access<p>Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells</p>
Author(s) -
Shuchen Chen,
Yu-Zhu Diao,
Zihan Zhao,
Xiaoling Li
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s245257
Subject(s) - erlotinib , kras , cancer research , gefitinib , gene knockdown , tyrosine kinase , lung cancer , mutant , medicine , cell culture , cancer , biology , epidermal growth factor receptor , colorectal cancer , receptor , gene , genetics
Lung cancer has the highest incidence among solid tumors in men and is the third most common cancer in women. Despite improved understanding of genomic and mutational landscape in non-small cell lung cancer (NSCLC), the five-year survival in these patients has remained stagnant at a dismal 15%. The first line of treatment commonly adapted for NSCLC patients with somatic mutation in EGFR is tyrosine kinase inhibitor gefitinib or erlotinib. EGFR mutant cells seem to be intrinsically sensitive to tyrosine kinase inhibitors; however, the remaining 20-30% patients are resistant to tyrosine kinase inhibitor.